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Topical Enzyme-Replacement Therapy Restores
Transglutaminase 1 Activity and Corrects Architecture
of Transglutaminase-1-Deficient Skin Grafts
Karin Aufenvenne,1,* Fernando Larcher,2 Ingrid Hausser,3,4,5 Blanca Duarte,2 Vinzenz Oji,1
Heike Nikolenko,6 Marcela Del Rio,2,7 Margitta Dathe,6 and Heiko Traupe1,*
Transglutaminase-1 (TG1)-deficient autosomal-recessive congenital ichthyosis (ARCI) is a rare and severe genetic skin disease caused by
mutations in TGM1. It is characterized by collodion babies at birth, dramatically increased transepidermal water loss (TEWL), and
lifelong pronounced scaling. The disease has a tremendous burden, including the problem of stigmatization. Currently, no therapy tar-
geting the molecular cause is available, and the therapeutic situation is deplorable. In this study, we developed the basis for a causative
therapy aiming at the delivery of the enzyme to the inner site of the keratinocytes’ plasma membrane. We prepared sterically stabilized
liposomes with encapsulated recombinant human TG1 (rhTG1) and equipped with a highly cationic lipopeptide vector to mediate
cellular uptake. The liposomes overcame the problems of insufficient cutaneous delivery andmembrane penetration and provided excel-
lent availability and activity of rhTG1 in primary keratinocytes. To demonstrate the general feasibility of this therapeutic approach in a
humanized context, we used a skin-humanized mouse model. Treatment with rhTG1 liposomes resulted in considerable improvement
of the ichthyosis phenotype and in normalization of the regenerated ARCI skin: in situ monitoring showed a restoration of TG1 activity,
and cholesterol clefts vanished ultrastructurally. Measurement of TEWL revealed a restoration of epidermal barrier function. We regard
this aspect as a major advance over available nonspecific approaches making use of, for example, retinoid creams. We conclude that this
topical approach is a promising strategy for restoring epidermal integrity and barrier function and provides a causal cure for individuals
with TG1 deficiency.Introduction
Transglutaminase 1 (TG1) is an intracellular key enzyme
for the formation of the cornified envelope (CE), which
acts as a mechanical barrier to protect against transepider-
mal water loss (TEWL) and infectious agents. TG1 is found
in the upper differentiated layers of the epidermis and in
hair follicles and shows a complex pattern of activities
given that it exists in multiple cytosolic and membrane-
anchored forms in terminally differentiating keratino-
cytes.1–3 It catalyzes the covalent crosslinking of numerous
structural CE proteins, including involucrin, loricrin,
filaggrin, and small proline-rich proteins, through the for-
mation of Nε-(g-glutamyl) lysine isopeptide bonds. In
contrast to other transglutaminases (TGs), TG1 is anchored
to the inner plasma membrane of keratinocytes. This
membrane localization is thought to be essential for the
assembly of CE components.4 Another important function
is the stabilization of the lipid lamella structures of the
corneocyte lipid envelope via attachment of long-chain
u-hydroxyceramides to involucrin.5
Mutations in TGM1 result in the severe and ultra-rare
genetic skin disease autosomal-recessive congenital ich-
thyosis (ARCI [MIM 242300]).6,7 Individuals with ARCI
due to TG1 deficiency are born as collodion babies with
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of life. After shedding, dark-gray or brownish plate-like
scales develop and usually affect the entire integument.
Loss of TG1 function results in an impaired epidermal
barrier with dramatically increased TEWL, causing the
inherent clinical problem of dehydration, which can be
life threatening, especially during the first weeks of life.
Other TGs (e.g., TG2, TG3, and TG5) are also active in
different epidermal layers but fail to compensate for TG1
activity.8 For example, TG3 catalyzes the intramolecular
linkage or dimerization of loricrin monomers in the cyto-
plasm but cannot accomplish the multimerization of lori-
crin at the inner surface of the plasmamembrane catalyzed
by TG1.9
In addition to clinical examination and sequencing of
TGM1, in situ monitoring of TG1 activity on cryosections
is an important tool for rapid diagnosis of TG1 defi-
ciency.10 Further confirming the diagnosis, ultrastructural
analysis of the stratum corneum showed cholesterol clefts,
which are important markers for TG1-deficient ARCI.11
Currently, no specific therapeutic approach targeting the
molecular cause of TG1 deficiency exists. All available
treatment modalities are insufficient: they are directed at
improving symptoms and can only provide symptomatic
relief. Therefore, many affected individuals struggle with
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hours a day with treatment of their skin. The burden of
TG1-deficient ARCI is tremendous.12
Because of the disappointing therapeutic situation, we
wanted to develop a targeted topical enzyme-replacement
therapy for TG1-deficient ARCI. To overcome the problems
of insufficient cutaneous delivery, particularly insufficient
membrane penetration of drugs, there is a need for a carrier
system tagged with an uptake-facilitating ligand that de-
livers the enzyme at the site of action into keratinocytes.
Here, we describe the development of sterically stabilized
liposomal preparations with encapsulated recombinant
human TG1 (rhTG1). A highly cationic, uptake-mediating
lipopeptide13 was incorporated into the liposomal surface.
We show that the rhTG1 liposomes were internalized
into cultured primary keratinocytes derived from individ-
uals with TG1 deficiency and demonstrate the restoration
of intracellular TG1 activity. Furthermore, this topical
approachwas tested in apreviously developed skin-human-
ized mouse model for TG1-deficient ARCI14 with the use of
different rhTG1 concentrations. Treatment of these mice
resulted in a clearly dosage-dependent and considerable
improvement of the ichthyosis phenotype and in normali-
zation of the regenerated ARCI skin: in situ monitoring
revealed a restoration of TG1 activity, and cholesterol clefts
vanished ultrastructurally. Immunohistochemical staining
of TG1 substrates showed a normalization of the distribu-
tion patterns. Measurement of TEWL revealed that normal
epidermal barrier function was maintained.Subjects and Methods
Study Approval
This study was conducted according to Declaration of Helsinki
principles and was approved by the institutional review board of
the University Hospital of Mu¨nster. All individuals enrolled gave
their informed consent.
All animal studies were approved by the institutional review
board of the Centro de Investigaciones Energe´ticas, Medioambien-
tales, y Tecnolo´gicas (CIEMAT), and all experimental procedures
were conducted according to European and Spanish laws and
regulations.
Subjects
Affected individuals were recruited in our specialized outpatient
clinic and had previously been characterized by clinical, immu-
nohistologic, ultrastructural, biochemical, and molecular genetic
means.14 Biopsies were taken under local anesthesia.
Animals
Nude (nu/nu, NMRI background) mice were purchased from Elev-
age-Janvier and were housed individually in pathogen-free
conditions at the CIEMAT Laboratory Animals Facility (Spanish
registration number 28079-21 A).
Insect Cell Culture, Recombinant Expression, and
Purification of Human TG1
Spodoptera frugiperda cells (Sf9 cells) and BTI-TN-5B1-4 insect cells
were cultured according to the manufacturer’s instructions.The AmericA full-length cDNA construct of human TG1, fl hTGk His, was
designed for recombinant protein production in Baculovirus-
infected insect cells, and this was followed by Ni-NTA chromatog-
raphy for purification. Successful insertion of the C-terminal
6xHis-tag via PCR and subcloning was verified by sequencing
(Seqlab). The vector pENTR3C fl hTGk his was incubated with
BaculoDirect linear DNA according to the manufacturer’s instruc-
tions. Evolving Baculovirus clones were analyzed by PCR.
For transfection, Sf9 cells were plated in a density of 83 105 cells
per well in a 6-well plate. The transfection procedure was per-
formed according to the manufacturer’s instructions. Ninety-six
hours after transfection, medium was collected and stored at 4C
in the dark. This baculoviral P1 stock was amplified by the infec-
tion of 1.4 3 107 Sf9 cells with the P1 stock solution (viral titer:
0.5 3 106 pfu/ml), and cells were incubated for 96 hr in Grace’s
medium supplemented with 100 mM ganciclovir for selection of
recombinant viruses. P2 viral stock was isolated and stored at
4C. For definition of the viral titers, plaque assays were performed
according to the manufacturer’s instructions.
Protein production was performed in 400 ml suspension
cultures of BTI-TN-5B1-4 insect cells growing in ExpressFive SFM
in Fernbach-flasks for 96 hr. Cells were infected at a density of
2 3 106 cells/ml with an amplified viral stock at a multiplicity of
infection of ~10. rhTG1 was purified from the media by ammo-
nium sulfate precipitation (65% saturation). Pellets were dissolved
in a 1/20 volume of 50 mM NaH2PO4, 300 mM NaCl, pH 8.0 and
dialyzed against 50 mM NaH2PO4, 300 mM NaCl, 10 mM imid-
azole, pH 8.0. Afterward, the protein solution was incubated
with Ni-NTA material (QIAGEN) overnight at 6C. Protein was
eluted with 50 mM NaH2PO4, 300 mM NaCl, 120 mM imidazole,
pH 8.0 under native conditions.SDS-PAGE and Immunoblotting
Protein samples derived from purification were assayed for TG1
content by immunoblotting. Samples were subjected to 10%
SDS-PAGE under reducing conditions and transferred onto a poly-
vinylidene difluoride membrane by electroblotting. Membranes
were saturated with 5% BSA in TBS, incubated with the first anti-
body, and later incubated with horseradish-peroxidase-conjugated
anti-IgG.Assay of Enzymatic Activity
Enzymatic activity of rhTG1 was analyzed via fluorescence spec-
trometry (LS55, Perkin Elmer; FLWINLAB software) at an emission
wavelength of 332 nm and an excitation wavelength of 500 nm
with a slit of 5.0 nm for 15 min as described previously.15Liposome Preparation
Small unilamellar vesicles (SUVs) and large unilamellar vesicles
(LUVs) were prepared as described elsewhere.13 In brief, dry egg
phosphatidylcholine (egg-PC), poly(ethylene glycol)-2000-dipal-
mitoyl-phosphatidylethanolamine (PEG-PE) (Avanti Polar Lipids),
and cholesterol (Sigma-Aldrich) were suspended by vortexing
in Tris buffer containing rhTG1 (0.1 mg/ml). The suspensions
were sonicated (Labsonic L instrument, B. Braun) or extruded
(MiniExtruder, Avestin) for obtaining SUVs or LUVs, respectively.
Vesicle diameter was checked on a Coulter N4 Plus particle sizer
(BeckmanCoulter). The lipid concentration was determined by
phosphorous analysis.16 Appropriate volumesof the liposomal sus-
pension and an aqueous solution of the lipopeptideweremixed for
achieving the desired peptide-liposome complexes. For uptakean Journal of Human Genetics 93, 620–630, October 3, 2013 621
studies, a tiny concentration of rhodamin-labeled dipalmitoyl-
phosphatidylethanolamine (Rhod-PE) was used as a lipid marker,
and the peptide was carboxyfluorescein labeled as described
before.17
Primary Cultures of Normal and TG1-Deficient
Human Keratinocytes and Fibroblasts
Primary keratinocytes and fibroblasts were obtained by enzymatic
digestion from 3–5 mm punch biopsies according to a standard
protocol described previously.14 In brief, biopsies were incubated
overnight at 4C in buffer containing 0.5 mg/ml protease X
(Sigma-Aldrich). Epidermal sheets were peeled off the dermis
and incubated in 0.25% trypsin and 0.02% EDTA (PAA) for
achieving single-cell suspension and were resuspended in
serum-free culture medium supplemented with 10 ng/ml EGF,
50 mg/ml bovine pituitary extract (BPE) (all from Life Technolo-
gies), and 2 mM glutamine (PAA).
For obtaining fibroblasts, the dermis was incubated in buffer
containing 0.5 mg/ml collagenase IA (Sigma-Aldrich), and cells
were resuspended in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum and 2 mM glutamine (PAA).
For inducing differentiation, keratinocytes were incubated with
1.2 mM CaCl2 for 48 hr.
Confocal Laser Scanning Microscopy
For uptake studies of rhTG1 liposomes with the use of confocal
laser-scanning microscopy (CLSM), cells were seeded on poly-L-
lysine-coated coverslips (30 mm) positioned in 35 mm plastic cul-
ture dishes and cultured in serum-free medium supplemented
with 10 ng/ml EGF, 50 mg/ml BPE (all from Life Technologies),
and 2 mM glutamine (PAA) for 2 days. Differentiated cells were
incubated with 1.2 mM CaCl2. Cells were washed with Dulbecco’s
PBS (pH 7.4) supplemented with 1 g/l D-glucose (Biochrom)
and exposed to rhTG1 liposomal formulations for 1 hr at 37C.
CLSM pictures were taken with an LSM 510 inverted confocal
laser-scanning microscope equipped with a Plan-Neofluar
1003/1.3 oil objective (Carl Zeiss) as described previously.13,18
Carboxyfluorescein and rhodamine were excited with a 200 mW
argon laser at 488 nm and a 15 mWHeNe laser at 543 nm, respec-
tively, and pictures were taken with a BP505-530 bandpass filter
and a LP650 cutoff filter, respectively. Cell viability was checked
by trypan-blue exclusion. The dye was excited at 633 nm with
the HeNe laser, and emission was recorded with a LP650 cutoff
filter. Image acquisition was done sequentially for minimizing
cross-talk between the fluorophores.
Bioengineered Skin Preparation and Grafting to
Immunodeficient Mice
Bioengineered skin preparation and grafting to immunodeficient
mice were performed as described previously.14,19 In brief, a fibrin-
ogen solution containing 5 3 105 dermal fibroblasts, 500 IU of
bovine aprotinin (Trasylol, Bayer), and 0.025 mM CaCl2 with 11
IU of bovine thrombin (Sigma-Aldrich) was prepared. Finally,
the mixture was poured in 6-well plates and allowed to clot at
37C. Keratinocytes derived from individuals with TG1-deficient
ARCI (13 105 to 53 105 cells per well) were seeded on the dermal
equivalent so that the epidermal layer could form. When
confluent, bioengineered skins were grafted onto immunodefi-
cient mice. Grafting was performed under sterile conditions with
6-week-old female nude mice. Generally, the regenerated human
skin became visible within 4–6 weeks after grafting.622 The American Journal of Human Genetics 93, 620–630, OctoberUltrastructural Analysis and Histology of Treated
Engrafted Human Skin
All graft specimens were fixed for at least 2 hr at room temperature
in a 3% glutaraldehyde solution in 0.1 M cacodylate buffer (pH
7.4), cut into pieces of approximately 1 mm3, washed in buffer,
postfixed for 1 hr at 4C in 1% osmium tetroxide, rinsed in water,
dehydrated through graded ethanol solutions, transferred into
propylene oxide, and embedded in epoxy resin (glycidether
100). Semithin sections were stained with methylene blue. Ultra-
thin sections were treated with uranyl acetate and lead citrate.
For negative staining of LUVs, a drop of LUV preparation was
placed onto formvar-coated copper grids for 2 min, and then
almost all solution was removed with filter paper. Grids were
placed onto a drop of 1% aqueous uranyl acetate solution for
2min. Excessive fluid was removed, and the samples were air-dried
at room temperature. All specimens were examined with a Zeiss
EM900 electron microscope equipped with a high-speed slow-
scan CCD camera and ImageSP software (Tro¨ndle).
In Situ Monitoring of Transglutaminase Activity and
Immunohistochemistry
In situ monitoring of transglutaminase activity on cryosections
was performed as described elsewhere.10 For immunohistochem-
istry, unfixed or acetone-fixed cryosections were incubated with
the following primary antibodies: loricrin (Covance), involucrin
(Sigma-Aldrich), filaggrin (Novocastra), and plasminogen acti-
vator inhibitor 2 (PAI-2, Santa Cruz Biotechnology). Slides were
viewed with an Axioskop 2 microscope, and digital images were
taken with an AxioCam HR video camera and AxioVision 3.0
software (Carl Zeiss).
Analysis of Epidermal Permeability Barrier Function
To determine the barrier function, TEWL was measured on the
back (graft) of the mice with the use of a noninvasive electronic
device, Tewameter TM 300 (Courage & Khazaka). All mice were
acclimatized for 15 min under standard conditions (20C and
45% humidity). Measurements were performed every second day
before the next treatment by the same investigator (K.A.).Results
Recombinant Protein Production and Activity of
Full-Length Human TG1
The full-length TG1 his cDNA construct was designed
for expression in baculovirus-infected insect cells; subse-
quently,Ni-NTA-chromatographywasperformed for purifi-
cation. Successful insertion of theC-terminal hexahistidine
tag (his-tag) was verified by DNA sequencing. After amplifi-
cation of recombinant baculoviruses, infection of BTI-TN-
5B1-4 insect cells resulted in a protein with a molecular
mass of about 92 kDa, as determined by SDS-PAGE. This
was identified as full-length human TG1 by immunoblot-
ting with TG1 and his-tag-specific antibodies, which gave
similar results. rhTG1 could be purified to homogeneity at
yields of up to 7 mg/l of cell-culture medium (Figures S1A
and S1B, available online). The fluorimetric activity assay
using cadaverin as a substrate for rhTG1, which was incor-
porated into casein, showed a specific activity of around
1,000 U/mg (data not shown).3, 2013
Figure 1. Schematic Presentation and
Ultrastructural Appearance of rhTG1 LUVs
(A) The cationic lipopeptide is an apoE-
derived dipalmitoylated tandem dimer
with or without a fluorescence marker.
(B) Electron microscopy of representative
LUVs (~200 nm; negative staining).Development of a Vector-Coupled Liposomal Carrier
System for rhTG1
To overcome the problems of insufficient cutaneous
delivery and intracellular availability of the enzyme, we
encapsulated rhTG1 in liposomes of different diameters:
50 nm for SUVs, 100 and 200 nm for LUVs, and
>1,500 nm for multilamellar large vesicles (MLVs), which
were sterically stabilized with PEG-PE. The liposomal
carriers were modified with a highly cationic peptide
sequence derived from apoE.13,20 The lipopeptide rapidly
bound to liposomes and served as a vector to facilitate
the carrier transport across the membrane of keratino-
cytes. A schematic presentation of the developed lipo-
somes and their ultrastructure is given in Figures 1A
and 1B. Four different liposomal formulations, prepared
with BSA as a model protein (5 mg/ml) (Table S1),
were used for characterizing the diameter and uniformity,
inner volume, amount of encapsulated protein, and sta-
bility of the carriers at different temperatures. Properties
such as high stability, uniformity, and high theoretical
inner volume made LUVs of 200 nm in diameter
and MLVs favorable candidates for further cell-culture
experiments.
Cellular Uptake of rhTG1 LUV Formulations
Cellular uptake of rhTG1 LUV and rhTG1 MLV formula-
tions into differentiated and undifferentiated kerati-
nocytes of normal individuals and individuals with
TG1-deficient ARCI was measured via CLSM (Figure 2A,
Figures S2A and S2B, and data not shown). The two fluo-
rescence labels, carboxyfluorescein (green fluorescence)
for the lipopeptide and Rhod-PE (red fluorescence) for
the lipid matrix, allowed confirmation of the internaliza-
tion of the complete liposome (Figure 2A, merge). Inter-
nalization of the rhTG1 LUVs occurred in differentiated
and undifferentiated ARCI cells (TGM1/) and in undif-
ferentiated normal cells (TGM1þ/þ). Uptake into differ-
entiated normal cells in comparison to ARCI cells was
markedly reduced. Large rhTG1 MLVs and liposomes
without the lipopeptide vector were not internalized
into the cells (data not shown). Subsequent immunoblot
analysis confirmed the uptake of the enzyme after incuba-
tion with rhTG1 LUV preparations (Figure 2B). Using
a his-tag antibody that only detects the recombinantThe American Journal of Human Gehis-tagged full-length form of TG1,
we found rhTG1 only in cells incu-
bated with rhTG1 LUV formula-
tions. In accordance with the CLSMresults, rhTG1 could not be detected in normal differen-
tiated cells.
Intracellular Activity of rhTG1 in Cultured Primary
Keratinocytes
Intracellular activity of rhTG1 after internalization of
rhTG1 LUVs into cultured primary keratinocytes was
monitored with the in situ activity assay on cryosections
(Figure 3). After keratinocytes derived from individuals
with TG1-deficient ARCI were incubated with rhTG1
LUV preparations, cells were trypsinized and immediately
frozen in liquid nitrogen. The intracellular activity of
rhTG1 in differentiated and undifferentiated ARCI kerati-
nocytes was comparable to that detected in normal differ-
entiated keratinocytes.
In Vivo Testing of rhTG1 LUVs: Evidence of a
Dosage-Dependent Effect
For in vivo testing of rhTG1 LUV formulations, we used
the previously developed humanized ARCI mouse
model.14 This model overcomes the drawback of the
classical Tgm1-knockout mouse model, i.e., lethality
within 3–4 hr after birth and lack of faithful recapitula-
tion of the human skin phenotype.21 Furthermore, it
has the great advantage of testing the rhTG1 LUVs in a
humanized context. Eight weeks after grafting, TG1-defi-
cient human grafts were treated with different dosages
of liposomal preparations (40 ng rhTG1/cm2 and 2 ng
rhTG1/cm2). Empty liposomes without encapsulated
rhTG1 and a retinoid cream (0.05%) as a known and
potent nonspecific therapeutic for ARCI served as control
regimens.
After 14 days of treatment every second day, we observed
a considerable change in phenotype (Figure 4). Application
of rhTG1 LUVs resulted in a phenotypic change after the
second treatment (day 5) at both dosages. Application of
the high rhTG1 dosage (40 ng rhTG1/cm2) resulted in a
nearly complete normalization of the skin (Figure 4D).
Histology in some areas of the sections showed elongated
ridges and hyperproliferation, which can also be detected
in diseases such as psoriasis and Netherton syndrome
(MIM 256500), in which TG1 is overexpressed
(Figure 4I). In contrast, with 2 ng rhTG1/cm2, the treated
grafts showed residual scaly patches (Figure 4E) butnetics 93, 620–630, October 3, 2013 623
Figure 2. Measurement of Cellular Uptake of rhTG1 LUVs
TG1-deficient cells (TGM1/) were isolated from skin biopsies of an individual with TGM1 mutations (c.377G>A [(p.Arg126His] and
c.876þ2T>C [(p.Glu253Valfs*2]) associated with generalized TG1-deficient ARCI. Differentiated cells were incubated with 1.2 mM
CaCl2 for 48 hr to mimic cells of the upper differentiated cell layers.
(A) Internalization of rhTG1 LUVs into primary keratinocytes was measured via CLSM. Colors are as follows: red, Rhod-PE; green,
cationic lipopeptide with fluorescence marker; and blue, trypan-blue staining for visualization of intact cell membranes.
(B) Internalization of rhTG1 LUVs was confirmed by subsequent immunoblot analysis using a his-tag antibody, which only detects the
full-length recombinant TG1, for distinguishing rhTG1 from the wild-type TG1 in differentiated normal cells.without psoriasiform features (Figure 4J), indicating a
dosage-dependent effect. Also, treatment with the retinoid
cream after 7 days resulted in a clear normalization (Figures624 The American Journal of Human Genetics 93, 620–630, October4B and 4G), whereas treatment with empty liposomes did
not have any effect on phenotype or histology (Figures 4C
and 4H).3, 2013
Figure 3. Intracellular Activity of rhTG1
after Internalization into Primary Kerati-
nocytes
Intracellular activity of rhTG1 in cultured
keratinocytes was measured after trypsini-
zation. Only internalized rhTG1 was de-
tected. The TG1 activity in cells derived
from individuals with TG1-deficient ARCI
was restored after incubation with rhTG1
LUV preparations. EDTA was used as a
negative control.Diagnostic Markers: In Situ TG1 Activity and
Ultrastructure
After treatment of the skin-humanized mice, biopsies were
taken and investigated with regard to diagnosticmarkers of
TG1-deficient ARCI (Figure 5). The in situ activity assay on
cryosections (Figures 5A–5E) after treatment with rhTG1
LUV preparations showed a restoration of TG1 activity in
both samples (Figures 5D and 5E). In contrast, retinoid-
treated samples, as predicted, did not show a restoration
of TG1 activity (Figure 5C). As important ultrastructural
markers, the cholesterol clefts were no longer detectable
in the regenerated skin treated with 40 ng rhTG1/cm2
(Figure 5I). Compared to untreatedmice (Figure 5G) or reti-
noid-treated mice (Figure 5H), mice treated with the lower
dosage of 2 ng rhTG1/cm2 showed a marked decrease of
cholesterol clefts (Figure 5J). As expected, grafts treated
with empty LUVs did not show any change either macro-
scopically (Figures 5C and 5H) or in TG1 activity or ultra-
structure (data not shown).
Investigation of Differentiation Markers and TG1
Substrates
Investigation of several differentiation markers and TG1
substrates, such as involucrin, filaggrin, PAI-2, and loricrin,
with specific antibodies confirmed the results of the in situ
monitoring of TG1 activity and ultrastructural investiga-
tions. These markers showed a more diffuse and slightly
shifted distribution in regenerated TG1-deficient grafts
and in human TG1-deficient skin compared to normal
skin (Figures S3A, S3F, S3K, and S3P). Compared to staining
in untreated mice (Figures S3B, S3G, S3L, and S3Q) or reti-
noid-treated mice (Figures S3C, S3H, S3M, and S3R), stain-
ing of filaggrin (Figures S3D and S3E), involucrin (Figures
S3I and S3J), PAI-2 (Figures S3N and S3O), and loricrin (Fig-The American Journal of Human Geures S3S and S3T) inmice treated with
rhTG1 LUV preparations revealed
a normalization of the distribution
patterns.
Measurement of TEWL
To further investigate the effect of
the rhTG1 LUV preparations on
epidermal barrier function, we per-
formed measurements of TEWL
during the 14 days of application(Figure 6). Every second day prior to the next treatment
with rhTG1 LUV preparations or the retinoid cream, we
measured the change in TEWL. Untreated mice did not
show an increase in TEWL (Figure 6, before treatment).
After treatment of regenerated TG1-deficient skin grafts
with the retinoid cream, TEWL was dramatically increased
to a very critical level (40.62 5 2.11 g/m2h on day 5) but
seemed to normalize to some degree during the treatment
(16.18 5 0.46 g/m2h on day 12). Treatment of the skin
grafts with both rhTG1 dosages (40 or 2 ng rhTG1/cm2)
did not result in any change in TEWL (3.07 5 1.36 to
5.7 5 2.28 g/m2h). The values remained in the ‘‘very
good’’ range.
Discussion
Individuals who suffer from TG1-deficient ARCI are
currently in a deplorable situation. Safe and efficient treat-
ment modalities are lacking. Because of this situation and
the fact that TGM1 mutations account for up to 48%
(about 55% in the United States) of all ARCI cases,22,23
we have developed the experimental basis for an
enzyme-replacement therapy for individuals suffering
from TG1-deficient ARCI. We show that a topical approach
using a formulation of liposomal-encapsulated rhTG1 is
suitable for restoring TG1 activity in the upper stratified
layers of the epidermis for reconstituting epidermal integ-
rity and barrier function.
Of particular importance are our in vivo experiments us-
ing the skin-humanized mouse model with two different
dosages of rhTG1 encapsulated in vector-coupled sterically
stabilized liposomes. We have shown that the liposomes
used in our experiments overcame the enormous prob-
lem of cutaneous delivery and actually penetrated thenetics 93, 620–630, October 3, 2013 625
Figure 4. Phenotype and Histology of Regenerated TG1-Deficient Skin Grafts in a Skin-Humanized Mouse Model before and after
Application of rhTG1 LUV Preparations
Phenotypic changes in mice treated with 40 ng rhTG1/cm2 (n ¼ 3) were observed after the second application (day 5) (D). Grafts treated
with 2 ng rhTG1/cm2 (n ¼ 3) after 14 days showed a minor effect with residual hyperkeratotic patches, suggesting dose dependency (E).
Compared to untreated grafts (A and F), regenerated skin treated with empty LUVs showed no change in phenotype or histology (C and
H). Treatment with a retinoid cream resulted in a phenotypic change after the first application but also with residual hyperkeratosis (B
and G) as described above for treatment with the lower rhTG1 dosage (E). Histology shows a clear reduction of the very thick and packed
cornified layer and psoriasiform signs at some sites of the sections only after treatment with 40 ng rhTG1/cm2. The bottom row depicts
methylene-blue staining of semithin sections.membrane of keratinocytes, which offers tremendous ther-
apeutic possibilities, as well as for other genodermatoses.
The ichthyosis phenotype on skin-humanized mice van-
ished in a dosage-dependent manner, which even applied
to ultrastructural markers of TG1 deficiency, namely the
presence of cholesterol clefts in the stratum corneum.
Moreover, in situ monitoring of TG1 activity on cryosec-
tions demonstrated a restoration of TG1 activity in regen-
erated skin grafts treated with 40 and 2 ng rhTG1/cm2.
Furthermore, distribution patterns of a number of
epidermal differentiation markers, such as loricrin, filag-
grin, involucrin, and PAI-2, showed normalization. The
fact that the higher rhTG1 dosage used was associated
with psoriasiform epidermal hyperplasia in some histolog-
ic sections is a further convincing argument that this
hyperplasia directly relates to restored TG1 activity. Similar
histologic features are found in skin diseases characterized
by epidermal hyperproliferation and TG1 hyperactiv-
ity, such as psoriasis vulgaris (MIM 177900) and Netherton
syndrome.24,25 We assume that the used 40 ng rhTG1/cm2
dosage is too high, and we expect even better results from
optimizing the liposomal formulation with respect to
composition and concentration of rhTG1.
To further investigate the effect of the rhTG1 LUV prep-
arations on epidermal barrier function, we performedmea-
surements of TEWL. The development of ichthyosiform
skin in ARCI is thought to be a homeostatic response to
compensate for defective permeability barrier function in
TG1 deficiency.7 Untreated mice displayed a compact
hyperkeratosis and therefore did not show an increase in
TEWL.26 Despite the clear reduction of the very thick626 The American Journal of Human Genetics 93, 620–630, Octoberand packed cornified layer, treatment with both rhTG1
dosages did not result in any change in TEWL, indicating
a maintenance of epidermal barrier function and integrity
as a result of the restoration of TG1 activity. In contrast, af-
ter treatment of regenerated ARCI skin with the retinoid
cream, TEWL dramatically increased. This observation is
in line with our expectations given that retinoid treatment
decreases the thickness of the stratum corneum but does
not correct TG1 deficiency and therefore does not restore
epidermal barrier function.
The concept of enzyme-replacement therapy has already
gained clinical significance in different lysosomal-storage
diseases, such as Fabry disease (MIM 301500), mucopoly-
saccharidosis type II (MIM 309900), and Gaucher disease
(MIM 230800).27–29 Uptake of enzymes involved in lyso-
somal-storage disease is driven by endocytosis. The fate
of endocytotic vesicles by the formation of endosomes
and lysosomes is well established.30
So that rhTG1 is accessible at the inner site of the plasma
membrane of differentiating keratinocytes, there is a need
for efficient transmembrane transport. Liposomes have
received widespread attention as drug delivery systems.
They are capable of incorporating and delivering hydro-
philic and hydrophobic drugs (among which are peptides
and proteins), are biodegradable, and show good biocom-
patibility, low toxicity, and minimal activation of the im-
mune system.31–33 By altering the biodistribution and
protecting the entrapped materials from inactivation by
host defense mechanisms (e.g., extracellular proteases),
liposomes can be used for target-specific drug delivery. Nat-
ural phospholipids, such as phosphatidylcholine, have3, 2013
Figure 5. Diagnostic Markers of Normal Human Skin in Comparison to Regenerated Human TG1-Deficient Skin before and after
Application of rhTG1 LUV Preparations
Normal human skin showed a pericellular distribution of TG1 activity in the granular layer of the epidermis (A). Cholesterol clefts in the
stratum corneum were not present (F). Untreated human skin grafts and grafts treated with a retinoid cream showed cholesterol clefts
within the stratum corneum (G andH), whereas TG1 activity was absent (B and C). After treatment of regenerated skin grafts with rhTG1
LUV formulations, the epidermis normalized: TG1 activity was detected with both dosages (D and E), and the formation of cholesterol
clefts vanished (I) or was markedly reduced (J). ‘‘CC’’ stands for cholesterol cleft.been commonly used to form liposomes. Cholesterol re-
duces the permeability to water-soluble molecules and en-
hances the stability in biological fluids.34 PEGylation
further enhances carrier stability and circulation time
and improves pharmacokinetics and pharmacodynamics
of encapsulated compounds by protecting from enzymatic
degradation, reduced renal clearance, and limited immu-
nogenic and antigenic reactions.35 Our optimized pep-
tide-modified liposomal preparation proved to be highly
efficient in the delivery of rhTG1 into keratinocytes and
in an in vivo mouse model.
The similarity in lipid composition of the liposomes and
membranes of keratinocytes might enable the liposomes
to penetrate into the epidermal barrier more efficiently
than other application forms.36 Subsequent changes in
the hydration spheres of the membrane layer might
decrease the retarding action of the skin cell layer with
the consequence of improved diffusion of the liposomes.
This might result in an increase in drug absorption into
the epidermis and a decrease in drug clearance.37 The
diameter of liposomes is an important factor in therapeutic
applications. We found that MLVs with a size distribution
in the range of >1,500 nm were not internalized into
keratinocytes. The preferred structures for drug delivery
are LUVs with a diameter between 100 and 500 nm.37,38
Our carrier-optimizing experiments confirm these early
studies (Table S1).
To mediate cellular uptake, the vesicles were modified
with a highly cationic lipopeptide. The apoE-derivedThe Americsequence bears characteristics of so-called cell-penetrating
peptides, which are able to shuttle attached cargos across
cellular barriers and comprise binding sites for the LDL
receptor and for cell-surface heparan sulfate proteoglycans,
two ubiquitous mammalian membrane constituents able
to mediate cellular uptake.13,20 In this study, the lipopep-
tide was proven to be highly efficient in mediating the
transport of rhTG1 LUVs across the membrane of keratino-
cytes. Cells exposed to liposomal preparations without the
lipopeptide vector did not show intracellular fluorescence,
indicating the importance of the developed vector-coupled
system. Internalization into differentiated normal cells
(TGM1þ/þ) was markedly lower than that into ARCI cells
(TGM1/). The activity of wild-type TG1, which catalyzes
the formation of an intact CE, probably prevents the
uptake of liposomes.
The cell-culture experiments validated the feasibility of a
topical approach, but they were not sufficient to demon-
strate that the clinical problems of ARCI can be corrected.
We therefore evaluated the reconstitution of epidermal
barrier formation in regenerated ARCI skin in vivo and
used a previously developed skin-humanized mouse
model.14 We had the great advantage of being able to test
our liposomal formulations in a humanized context. Note-
worthy, after 14 days of treatment with both dosages of
rhTG1 LUVs, we could not detect clinical signs of local
toxicity. Furthermore, our studies demonstrate an efficient
penetration of the vector-coupled rhTG1 LUVs through
the thick and packed stratum corneum.an Journal of Human Genetics 93, 620–630, October 3, 2013 627
Figure 6. Measurement of TEWL
Measurement of TEWL was done directly before the next treat-
ment of mice with rhTG1 LUV preparations or the retinoid cream
(n ¼ 4). As part of a homeostatic response to the barrier distur-
bance and for the prevention of TEWL, untreated animals devel-
oped compact hyperkeratosis and therefore did not show an
increase in TEWL before treatment. Treatment with the retinoid
cream resulted in dramatically increased TEWL, which seemed
to normalize during the treatment process. Compared to
untreated regenerated TG1-deficient grafts (before treatment) or
normal human skin (7.42 5 0.13 g/m2h), normal mouse skin
(4.91 5 2.58 g/m2h), and normal regenerated grafts (3.52 5
0.85 g/m2h) (data not shown), skin treated with the developed
rhTG1 LUV preparations maintained the physiological situation
and did not show an increase in TEWL. This indicates a restoration
of the epidermal barrier function after treatment with rhTG1 LUV
preparations. Values are given as means5 SEMs.As a control in our experiments, we used a retinoid
cream as a known and potent therapeutic agent for ARCI.
Considerable improvement of lesions was detected clini-
cally in the treated skin. After treatment with the retinoid
cream, we observed a considerable change in phenotype,
but cholesterol clefts still remained visible. The clear-cut
reduction of the cornified layer after application of the reti-
noid cream shows that the skin-humanized mouse model
also responded very well to a known treatment method.
It is known that this treatment, although effective, induces
side-effects such as mild pruritus, slight burning, and
mild to moderate skin irritation in humans, which limits
its use.39,40
Ex vivo gene therapy was reported for TG1 deficiency 15
years ago in an experimental model. Normal gene expres-
sion of TGM1 was restored, and a phenotype correction
was observed in engrafted lesional skin.41,42 This approach
has been abandoned and has never reached the clinic,
probably because of biological safety concerns associated
with this therapeutic modality.Supplemental Data
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This work was supported by the Bundesministerium fu¨r Bildung
und Forschung as part of the Network for Ichthyosis and
Related Keratinization Disorders (NIRK) (grants 01GM0901 and628 The American Journal of Human Genetics 93, 620–630, October01GM0902), the Foundation for Ichthyosis and Related Skin
Types, and the Selbsthilfe Ichthyose e.V. F.L. was supported in
part by the Instituto de Salud Carlos III (grant PI11/1225) and by
grant S2010/BMD-2359 from C.M. M.D.R. was supported by the
Ministerio de Ciencia y Innovacio´n (grant SAF2010-16976). The
work of M.D. was partially supported by Deutsche Forschungsge-
meinschaft (grant DA 324/9-1). We are very grateful to all indi-
viduals who participated in the study. Primary normal human
keratinocytes for uptake studies were kindly provided by the Insti-
tute of Pharmacy of Freie Universita¨t Berlin. The excellent tech-
nical assistance of Androniki Kolovou is gratefully acknowledged,
and Katrin Jordan is thanked very much for the biophysical char-
acterization of the liposomal formulations. Very special thanks go
to Brigitte Willis for her excellent work as the coordinator of the
NIRK. The European commission has awarded an orphan drug
designation for the therapeutic modality described in this article
(http://www.ema.europa.eu/ema).
Received: May 12, 2013
Revised: July 17, 2013
Accepted: August 1, 2013
Published: September 19, 2013Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.orgReferences
1. Goldsmith, L.A. (1983). Human epidermal transglutaminase.
J. Invest. Dermatol. 80, 39s–41s.
2. Rice, R.H., Rong, X.H., and Chakravarty, R. (1990). Proteolytic
release of keratinocyte transglutaminase. Biochem. J. 265,
351–357.
3. Steinert, P.M., Chung, S.I., and Kim, S.Y. (1996). Inactive
zymogen and highly active proteolytically processed mem-
brane-bound forms of the transglutaminase 1 enzyme in
human epidermal keratinocytes. Biochem. Biophys. Res.
Commun. 221, 101–106.
4. Candi, E., Schmidt, R., and Melino, G. (2005). The cornified
envelope: a model of cell death in the skin. Nat. Rev. Mol.
Cell Biol. 6, 328–340.
5. Nemes, Z., Marekov, L.N., Fe´su¨s, L., and Steinert, P.M.
(1999). A novel function for transglutaminase 1: attach-
ment of long-chain omega-hydroxyceramides to involucrin
by ester bond formation. Proc. Natl. Acad. Sci. USA 96,
8402–8407.
6. Russell, L.J., DiGiovanna, J.J., Rogers, G.R., Steinert, P.M.,
Hashem, N., Compton, J.G., and Bale, S.J. (1995). Mutations
in the gene for transglutaminase 1 in autosomal recessive
lamellar ichthyosis. Nat. Genet. 9, 279–283.
7. Oji, V., Tadini, G., Akiyama, M., Blanchet Bardon, C., Bod-
emer, C., Bourrat, E., Coudiere, P., DiGiovanna, J.J., Elias, P.,
Fischer, J., et al. (2010). Revised nomenclature and classifica-
tion of inherited ichthyoses: results of the First Ichthyosis
Consensus Conference in Sore`ze 2009. J. Am. Acad. Dermatol.
63, 607–641.
8. Hitomi, K. (2005). Transglutaminases in skin epidermis. Eur. J.
Dermatol. 15, 313–319.3, 2013
9. John, S., Thiebach, L., Frie, C., Mokkapati, S., Bechtel, M.,
Nischt, R., Rosser-Davies, S., Paulsson, M., and Smyth, N.
(2012). Epidermal transglutaminase (TGase 3) is required for
proper hair development, but not the formation of the
epidermal barrier. PLoS ONE 7, e34252.
10. Raghunath, M., Hennies, H.C., Velten, F., Wiebe, V., Steinert,
P.M., Reis, A., and Traupe, H. (1998). A novel in situ method
for the detection of deficient transglutaminase activity in
the skin. Arch. Dermatol. Res. 290, 621–627.
11. Laiho, E., Niemi, K.M., Ignatius, J., Kere, J., Palotie, A., and
Saarialho-Kere, U. (1999). Clinical and morphological correla-
tions for transglutaminase 1 gene mutations in autosomal
recessive congenital ichthyosis. Eur. J. Hum. Genet. 7,
625–632.
12. Kamalpour, L., Gammon, B., Chen, K.H., Veledar, E., Pavlis,
M., Rice, Z.P., and Chen, S.C. (2011). Resource utilization
and quality of life associated with congenital ichthyoses.
Pediatr. Dermatol. 28, 512–518.
13. Sauer, I., Nikolenko, H., Keller, S., Abu Ajaj, K., Bienert, M.,
and Dathe, M. (2006). Dipalmitoylation of a cellular uptake-
mediating apolipoprotein E-derived peptide as a promising
modification for stable anchorage in liposomal drug carriers.
Biochim. Biophys. Acta 1758, 552–561.
14. Aufenvenne, K., Rice, R.H., Hausser, I., Oji, V., Hennies,
H.C., Rio, M.D., Traupe, H., and Larcher, F. (2012). Long-
term faithful recapitulation of transglutaminase 1-deficient
lamellar ichthyosis in a skin-humanized mouse model, and
insights from proteomic studies. J. Invest. Dermatol. 132,
1918–1921.
15. Aufenvenne, K., Oji, V., Walker, T., Becker-Pauly, C., Hen-
nies, H.C., Sto¨cker, W., and Traupe, H. (2009). Transgluta-
minase-1 and bathing suit ichthyosis: molecular analysis
of gene/environment interactions. J. Invest. Dermatol. 129,
2068–2071.
16. Bo¨ttcher, C.J.F., Van Gent, C.M., and Pries, C. (1961). A rapid
and sensitive submicro phosphorus determination. Anal.
Chim. Acta 24, 203–204.
17. Leupold, E., Nikolenko, H., and Dathe,M. (2009). Apolipopro-
tein E peptide-modified colloidal carriers: the design deter-
mines the mechanism of uptake in vascular endothelial cells.
Biochim. Biophys. Acta 1788, 442–449.
18. Leupold, E., Nikolenko, H., Beyermann, M., and Dathe, M.
(2008). Insight into the role of HSPG in the cellular uptake
of apolipoprotein E-derived peptide micelles and liposomes.
Biochim. Biophys. Acta 1778, 2781–2789.
19. Del Rio, M., Larcher, F., Serrano, F., Meana, A., Mun˜oz, M.,
Garcia, M., Mun˜oz, E., Martin, C., Bernad, A., and Jorcano,
J.L. (2002). A preclinical model for the analysis of geneti-
cally modified human skin in vivo. Hum. Gene Ther. 13,
959–968.
20. Keller, S., Sauer, I., Strauss, H., Gast, K., Dathe, M., and Bienert,
M. (2005). Membrane-mimetic nanocarriers formed by a
dipalmitoylated cell-penetrating peptide. Angew. Chem. Int.
Ed. Engl. 44, 5252–5255.
21. Matsuki, M., Yamashita, F., Ishida-Yamamoto, A., Yamada, K.,
Kinoshita, C., Fushiki, S., Ueda, E., Morishima, Y., Tabata, K.,
Yasuno, H., et al. (1998). Defective stratum corneum and early
neonatal death in mice lacking the gene for transglutaminase
1 (keratinocyte transglutaminase). Proc. Natl. Acad. Sci. USA
95, 1044–1049.
22. Rodrı´guez-Pazos, L., Ginarte, M., Fachal, L., Toribio, J., Carra-
cedo, A., and Vega, A. (2011). Analysis of TGM1, ALOX12B,The AmericALOXE3, NIPAL4 and CYP4F22 in autosomal recessive
congenital ichthyosis from Galicia (NW Spain): evidence of
founder effects. Br. J. Dermatol. 165, 906–911.
23. Farasat, S., Wei, M.H., Herman, M., Liewehr, D.J., Steinberg,
S.M., Bale, S.J., Fleckman, P., and Toro, J.R. (2009). Novel
transglutaminase-1 mutations and genotype-phenotype
investigations of 104 patients with autosomal recessive
congenital ichthyosis in the USA. J. Med. Genet. 46,
103–111.
24. Raghunath, M., Tontsidou, L., Oji, V., Aufenvenne, K., Schu¨r-
meyer-Horst, F., Jayakumar, A., Sta¨nder, H., Smolle, J., Clay-
man, G.L., and Traupe, H. (2004). SPINK5 and Netherton
syndrome: novel mutations, demonstration of missing LEKTI,
and differential expression of transglutaminases. J. Invest.
Dermatol. 123, 474–483.
25. Oji, V., Oji, M.E., Adamini, N., Walker, T., Aufenvenne, K.,
Raghunath, M., and Traupe, H. (2006). Plasminogen activator
inhibitor-2 is expressed in different types of congenital ich-
thyosis: in vivo evidence for its cross-linking into the cornified
cell envelope by transglutaminase-1. Br. J. Dermatol. 154,
860–867.
26. Kuramoto, N., Takizawa, T., Takizawa, T., Matsuki, M.,
Morioka, H., Robinson, J.M., and Yamanishi, K. (2002). Devel-
opment of ichthyosiform skin compensates for defective
permeability barrier function in mice lacking transglutami-
nase 1. J. Clin. Invest. 109, 243–250.
27. Schaefer, R.M., Tylki-Szymanska, A., and Hilz, M.J. (2009).
Enzyme replacement therapy for Fabry disease: a systematic
review of available evidence. Drugs 69, 2179–2205.
28. Okuyama, T., Tanaka, A., Suzuki, Y., Ida, H., Tanaka, T., Cox,
G.F., Eto, Y., and Orii, T. (2010). Japan Elaprase Treatment
(JET) study: idursulfase enzyme replacement therapy in adult
patients with attenuated Hunter syndrome (Mucopolysac-
charidosis II, MPS II). Mol. Genet. Metab. 99, 18–25.
29. Tanaka, N., Saito, H., Ito, T., Momose, K., Ishida, F., Hora, K.,
Kiyosawa, K., and Ida, H. (2001). Initiation of enzyme replace-
ment therapy for an adult patient with asymptomatic type 1
Gaucher’s disease. Intern. Med. 40, 716–721.
30. De Duve, C. (1964). Principles of tissue fractionation. J. Theor.
Biol. 6, 33–59.
31. Mufamadi, M.S., Pillay, V., Choonara, Y.E., Du Toit, L.C.,
Modi, G., Naidoo, D., and Ndesendo, V.M. (2011). A review
on composite liposomal technologies for specialized drug
delivery. J. Drug Deliv. 2011, 939851.
32. Pierre, M.B., and Dos Santos Miranda Costa, I. (2011).
Liposomal systems as drug delivery vehicles for dermal
and transdermal applications. Arch. Dermatol. Res. 303,
607–621.
33. Fireman, S., Toledano, O., Neimann, K., Loboda, N., and
Dayan, N. (2011). A look at emerging delivery systems for
topical drug products. Dermatol. Ther. 24, 477–488.
34. Damen, J., Regts, J., and Scherphof, G. (1981). Transfer and
exchange of phospholipid between small unilamellar lipo-
somes and rat plasma high density lipoproteins. Dependence
on cholesterol content and phospholipid composition. Bio-
chim. Biophys. Acta 665, 538–545.
35. Li, S.D., andHuang, L. (2009). Nanoparticles evading the retic-
uloendothelial system: role of the supported bilayer. Biochim.
Biophys. Acta 1788, 2259–2266.
36. du Plessis, J., Egbaria, K., Ramachandran, C., and Weiner, N.
(1992). Topical delivery of liposomally encapsulated gamma-
interferon. Antiviral Res. 18, 259–265.an Journal of Human Genetics 93, 620–630, October 3, 2013 629
37. de Leeuw, J., de Vijlder, H.C., Bjerring, P., and Neumann, H.A.
(2009). Liposomes in dermatology today. J. Eur. Acad. Derma-
tol. Venereol. 23, 505–516.
38. Nagayasu, A., Uchiyama, K., and Kiwada, H. (1999). The size
of liposomes: a factor which affects their targeting efficiency
to tumors and therapeutic activity of liposomal antitumor
drugs. Adv. Drug Deliv. Rev. 40, 75–87.
39. Hofmann, B., Stege, H., Ruzicka, T., and Lehmann, P. (1999).
Effect of topical tazarotene in the treatment of congenital ich-
thyoses. Br. J. Dermatol. 141, 642–646.630 The American Journal of Human Genetics 93, 620–630, October40. Marulli, G.C., Campione, E., Chimenti, M.S., Terrinoni, A.,
Melino, G., and Bianchi, L. (2003). Type I lamellar ichthyosis
improved by tazarotene 0.1% gel. Clin. Exp. Dermatol. 28,
391–393.
41. Choate, K.A., and Khavari, P.A. (1997). Direct cutaneous gene
delivery in a human genetic skin disease. Hum. Gene Ther. 8,
1659–1665.
42. Choate, K.A., Medalie, D.A., Morgan, J.R., and Khavari, P.A.
(1996). Corrective gene transfer in the human skin disorder
lamellar ichthyosis. Nat. Med. 2, 1263–1267.3, 2013
